title: Follicular lymphoma patients with a high FLIPI score and a high tumor burden: a risk stratification model.
abstract: OBJECTIVE
  The widely accepted Follicular Lymphoma International Prognostic Index (FLIPI) divides patients into three risk groups based on the score of adverse prognostic factors. The estimated 5-year survival in patients with a high FLIPI score is around 50%. The aim of this study was to analyse the prognostic value of clinical and laboratory parameters that are not included in the FLIPI and the New Prognostic Index for Follicular Lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project (FLIPI2) indices, in follicular lymphoma (FL) patients with a high FLIPI score and high tumor burden.
  
  
  METHODS
  The retrospective analysis included 57 newly diagnosed patients with FL, a high FLIPI score and a high tumor burden. All the pa- tients were diagnosed and treated between April 2000 and June 2007 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade.
  
  
  RESULTS
  The patients with a histological grade > 1, erythrocyte sedimentation rate (ESR) 45 mm/h and hypoalbuminemia had a significantly worse overall survival (P = 0.015; p = 0.001; p = 0.008, respectively), while there was a tendency toward worse overall survival in the patients with an Eastern Cooperative Oncology Group (ECOG) > 1 (p = 0.075). Multivariate Cox regression analysis identified a histological grade > 1, ESR 45 mm/h and hypoalbuminemia as independent risk factors for a poor outcome. Based on a cumulative score of unfavourable prognostic factors, patients who had 0 or 1 unfavourable factors had a significantly better 5-year overall survival compared to patients with 2 or 3 risk factors (75% vs 24.1%, p = 0.000).
  
  
  CONCLUSIONS
  The obtained results suggest that from the examined prognostic parameters histological grade > 1, ESR 45 mm/h and hypoalbuminemia can contribute in defining patients who need more aggressive initial treatment approach, if two or three of these parameters are present on presentation.
authors.forename: Boško
authors.initials: B
authors.lastname: Andjelić
authors.forename: Milena
authors.initials: M
authors.lastname: Todorović-Balint
authors.forename: Darko
authors.initials: D
authors.lastname: Antić
authors.forename: Jelena
authors.initials: J
authors.lastname: Bila
authors.forename: Vladislava
authors.initials: V
authors.lastname: Djurašinović
authors.forename: Biljana
authors.initials: B
authors.lastname: Mihaljević
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood; D001799:Blood Sedimentation; D005260:Female; D006801:Humans; D008224:Lymphoma, Follicular / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D011237:Predictive Value of Tests; D011379:Prognosis; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D055771:Serbia; D012709:Serum Albumin / Q000032:analysis; D012720:Severity of Illness Index; D015996:Survival Rate; D047368:Tumor Burden
chemical_list: D014408:Biomarkers, Tumor; D012709:Serum Albumin